SNYRQ 10-K & 10-Q changes, risk factors and insider trading
Synergy CHC Corp. · OTC · Medicinal Chemicals & Botanical Products · CIK 1562733 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
New heading “While our exposure to international markets and foreign sourcing is limited, we may still be indirectly affected by global trade developments.”
New heading “In connection with the preparation of our consolidated financial statements as of and for the year ended December 31, 2025, management identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls over financial reporting, which may cause us to fail to meet our reporting obligations, result in material misstatements of our consolidated financial statements and could have a material adverse effect on our business and the market price of our common stock.”
Removed heading “We are a “controlled company” within the meaning of the Nasdaq rules and, as a result, qualify for, and may rely on, exemptions and relief from certain corporate governance requirements. If we rely on these exemptions, our stockholders will not have the same protections afforded to stockholders of companies that are subject to such requirements.”
Removed heading “A significant number of our total outstanding shares are restricted from immediate resale, but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.”
Largest changes
“We are committed to remediating the material weaknesses described above and continuing remediation efforts during 2026. We intend to initiate and implement several remediation measures including, but not limited to clearly define roles and responsibilities. As part of its remediation measures, to date, we have investigated additional procedures we can implement for segregation. …”see in full comparison
“In connection with the preparation of our consolidated financial statements as of and for the year ended December 31, 2025, management identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls over financial reporting, which may cause us to fail to meet our reporting obligations, result in material misstatements of our consolidated financial statements and could have a material adverse effect on our business and the market price of our …”see in full comparison
“As discussed below in Part II, Item 9A, “Controls and Procedures,” our management identified material weaknesses in implementation of segregation of duties and establishment of clearly defined roles within our finance and accounting functions. Moreover, management concluded that its internal control over financial reporting was not effective as of December 31, 2025, due to the material weaknesses. …”see in full comparison
“As a public company, we are required to maintain internal control over financial reporting, to report any material weaknesses in such internal control, and provide management’s attestation on internal control over financial reporting. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of an entity’s financial statements will not be prevented or detected on a timely basis. …”see in full comparison
“We are a “controlled company” within the meaning of the Nasdaq rules and, as a result, qualify for, and may rely on, exemptions and relief from certain corporate governance requirements. If we rely on these exemptions, our stockholders will not have the same protections afforded to stockholders of companies that are subject to such requirements.”see in full comparison
“A significant number of our total outstanding shares are restricted from immediate resale, but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.”see in full comparison
Full comparison: every changed paragraph (45)
An investment in our common
stock involves a high degree of risk. You should carefully consider the following risks and all of the other information contained in
this Annual Report before deciding whether to invest in our common stock. If any of the following risks are realized, our business, financial
condition andcondition, results of operations and cash flows could be materially and adversely affected. In that event, the trading price of our common
stock could
decline, and you could lose all or part of your investment in our common stock. Additional risks of which we are not presently
aware or
that we currently believe are immaterial may also harm our business andbusiness, results of operations.operations and cash flows. Some statements in
this Annual Report,
including such statements in the following risk factors, constitute forward-looking statements. See the
section entitled “Cautionary
Note Regarding Forward-Looking Statements.”
The U.S. nutritional
supplements supplements
retail industry is a large and highly fragmented industry with few barriers to entry. We compete against other domestic and
international international
manufacturers, specialty retailers, mass merchants, multi-level marketing organizations, mail-order and direct-to-consumer companies,
and e-commerce companies. This market is highly sensitive to the introduction of new products, which may rapidly capture a significant
share of the market. As certain products become more mainstream, with broader distribution, we may experience increased competition for
those products. Increased competition from companies that distribute through retail, e-commerce or wholesale channels could have
a material adverse effect on our financial condition andcondition, results of operations.operations and cash flows. Certain of our competitors may have significantly
greater greater
financial, technical and marketing resources than we do, and may be able to adapt to changes in consumer preferences more quickly,
devote devote
greater resources to the marketing and sale of their products, or generate greater brand recognition. In addition, our competitors
may may
be more effective and efficient in introducing new products. Furthermore, if we fail to maximize the efficiency of our ship direct
to to
customers strategies, or fail to provide our customers with an attractive omni-channel experience, our business andbusiness, results of operations
and cash flows could be materially and adversely affected. We may not be able to compete effectively, and any of the factors listed above
may cause price
reductions, reduced margins and losses of our market share.
Our failure to appropriately respond to
changing consumer preferences and demand for new products or product enhancements could significantly harm our relationship with customers
and our product sales, as well as our financial conditioncondition, operating results and operatingcash results.flows.
If we do not introduce new
products or make enhancements to meet the
changing needs of our customers in a timely manner, some of our products could be rendered obsolete,
which could negatively impact our
revenues, financial condition, operating results and operatingcash results.flows.
Certain retailers make up
a a
significant percentage of our products’ retail volume. For the year ended December 31, 2024,2025, our top two customers accounted for
73%79% of our net revenue. For the year ended December 31, 2023,2024, our top threetwo customers accounted for 78%73% of our netrevenue. revenue.
We sell products
to our customers under their standard vendor agreements. These vendor agreements do not include a term or duration as
sales under each
vendor agreement are generally made on a purchase order basis, and do not include any termination provisions. The loss
of sales of any
of our products in a major retailer, or the reduction of purchasing levels or the cancellation of any business from a
major retailer,
could have a material adverse effect on our business and financial performance. In addition, if we were to lose one or
more of these retailers
as a distribution channel for our products, we can make no assurances that we will be able to find a comparable
retailer to replace such
relationship or that we will be able to find a replacement at all, which could negatively impact our revenues,
financial condition, and
operating results.
While our exposure to international markets and foreign sourcing is limited, we may still be indirectly affected by global trade developments.
We primarily operate within the United States, and in 2025 and 2024, international sales accounted for 10.1% and 11.5%, respectively, of our total revenue. We purchase only finished goods from third-party manufacturers and do not engage in the direct sourcing of raw materials. This structure limits our direct exposure to international markets, tariffs, and global supply chain disruptions.
However, because our manufacturers may source raw materials from abroad, changes in international trade policies, tariffs, or geopolitical tensions could still affect our supply chain and cost of goods. Any disruptions or cost increases experienced by our manufacturers may impact the availability or pricing of the products we purchase. While our current structure mitigates many of the risks associated with global sourcing, we cannot eliminate the possibility that future global events or trade policies may have an adverse effect on our business, financial condition, results of operations or cash flows.
A downturn in the economy, economy
could affect
consumer purchases of discretionary items such as the health and wellness products that we offer, which could have an adverse
effect on
our business, financial condition, profitability, and cash flows.
As part of our growth strategy,
we have a history of pursuing acquisitions
of companies with products that are similar or complementary to those that we provide in our
businesses to better leverage our existing,
scalable infrastructure, and may continue to pursue this strategy in the future. These acquisitions
may involve significant cash expenditures,
debt incurrence, additional operating losses and expenses, and compliance risks that could
have a material adverse effect on our financial condition and
condition, results of operations.operations and cash flows.
In addition, these acquisitions
involve risks that the acquired businesses will not perform in accordance with expectations, that we may become liable for unforeseen
financial or business liabilities of the acquired businesses, including liabilities for failure to comply with healthcare regulations,
that the expected synergies associated with acquisitions will not be achieved, and that business judgments concerning the value, strengths,
and weaknesses of businesses acquired will prove incorrect, which could have a material adverse effect on our financial conditioncondition, results
of operations and
results ofcash operations.flows.
The nutritional supplement industry increasingly
relies on intellectual property rights and although we seek to ensure that we do not infringe the intellectual property rights of others,
there can be no assurance that third parties will not assert intellectual property infringement claims against us, which claims may result
in substantial costs and diversion of management and other resources and could have a material adverse effect on our business, financial
conditioncondition, operating results and operatingcash results.flows. Our inability to acquire, protect or maintain our intellectual property could harm our ability
to compete
or grow.
Recently it has become more
and more common for suppliers and competitors to apply for patents or develop proprietary technologies and processes. We seek to ensure
that we do not infringe the intellectual property rights of others, but there can be no assurance that third parties will not assert intellectual
property infringement claims against us. These developments could prevent us from offering or supplying competitive products or ingredients
in the marketplace. They could also result in litigation or threatened litigation against us related to alleged or actual infringement
of third-party rights. If an infringement claim is asserted or litigation is pursued, we may be required to obtain a license of rights,
pay royalties on a retrospective or prospective basis or terminate our manufacturing and marketing of our products that are alleged to
have infringed. Litigation with respect to such matters could result in substantial costs and diversion of management and other resources
and could have a material adverse effect on our business, financial condition andcondition, results of operations.operations and cash flows.
We have one U.S. patent
(which expires in April 2025) and numerous U.S. and
foreign trademarks and service marks. There can be no assurance that the protection
afforded by the patent and these trademarks and service marks will
provide us with a competitive advantage or that we will be able to
assert our intellectual property rights in infringement actions. We
may be required to defend our intellectual property against such infringement,
which could result in substantial costs and diversion of
management and other resources. In addition, results of such litigation are difficult
to predict and if we are not successful in defending
our intellectual property rights, this could have a material adverse effect on our
business, financial condition andcondition, results of operations.operations
and cash flows.
Trade secrets are difficult
to protect. We rely on trade secrets to
protect our proprietary knowledge, especially where we do not believe patent protection is appropriate
or obtainable, or where such patents
would be difficult to enforce. We rely in part on confidentiality agreements to protect our trade
secrets and other proprietary knowledge.
We cannot guarantee that we have entered into such agreements with each party that may have had
access to our proprietary knowledge, or
that such agreements, even if in place, will not be circumvented. These agreements may not effectively
prevent disclosure of proprietary
knowledge and may not provide an adequate remedy in the event of unauthorized disclosure of such information.
In addition, others may
independently discover our trade secrets and proprietary knowledge, in which case we may have no right to prevent
them from using such
trade secrets or proprietary knowledge to compete with us. Costly and time-consuming litigation could be necessary
to enforce and
determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could materially
adversely affect
our business, financial condition andcondition, results of operations.operations and cash flows.
We may experience product recalls, withdrawals
or seizures, which could materially and adversely affect our business, financial condition andcondition, results of operations.operations and cash flows.
We may be subject to product
recalls, withdrawals or seizures if any
of the products we sell are believed to cause injury or illness or if we are alleged to have violated
governmental regulations in the
manufacturing, labeling, promotion, sale or distribution of those products. A significant recall, withdrawal
or seizure of any of the
products we manufacture or sell may require significant management attention, would likely result in substantial
and unexpected costs
and may materially and adversely affect our business, financial condition or results of operations. Furthermore,
a recall, withdrawal
or seizure of any of our products may adversely affect consumer confidence in our brands and thus decrease consumer
demand for our products.
As is common in the nutritional supplements industry, we rely on our contract manufacturers and suppliers to
ensure that the products
they manufacture and sell to us comply with all applicable regulatory and legislative requirements. In general,
we seek representations
and warranties, indemnification and/or insurance from our contract manufacturers and suppliers. However, even
with adequate insurance
and indemnification, any claims of non-compliance could significantly damage our reputation and consumer
confidence in our products.
In addition, the failure of those products to comply with applicable regulatory and legislative requirements
could prevent us from marketing
the products or require us to recall or remove such products from the market, which in certain cases could
materially and adversely affect
our business, financial condition andcondition, results of operations.operations and cash flows.
Increases in the price or shortages of supply
of key raw materials could materially and adversely affect our business, financial condition andcondition, results of operations.operations and cash flows.
Our products are composed
of of
certain key raw materials. If the prices of these raw materials were to increase significantly, it could result in a significant increase
to us in the prices charged to us. Raw material prices may increase in the future, and we may not be able to pass on those increases to
customers who purchase our products. A significant increase in the price of raw materials that cannot be passed on to customers could
have a material adverse effect on our business, financial condition andcondition, results of operations.operations and cash flows.
We are exposed to credit
risk risk
primarily on our accounts receivable. We provide credit to our customers in the ordinary course of our business and perform ongoing
credit credit
evaluations. While we believe that our exposure to concentrations of credit risk with respect to accounts receivable is mitigated
by our
large retail partner base, and we make allowances for doubtful accounts, we nevertheless run the risk of our customers not being
able able
to meet their payment obligations, particularly in a future economic downturn. If a material number of our customers were not able
to to
meet their payment obligations, our results of operations and cash flows could be harmed.
Natural disasters and unusually adverse
weather conditions could cause permanent or temporary damage to our distribution centers, impair our ability to purchase, receive or replenish
inventory or cause customer traffic to decline, all of which could result in lost sales and otherwise materially and adversely affect
our results of operations.operations and cash flows.
The occurrence of one or
more more
natural disasters, such as hurricanes, fires, floods, earthquakes, tornadoes, high winds and other severe weather, could materially
and and
adversely affect our operations andoperations, results of operations.operations and cash flows. To the extent these events result in the suspension of shipping
by our distributors,
closure of our corporate headquarters, or a significant number of the stores in which our products are sold, or to
the extent they adversely
affect one or more of our key suppliers, our operations and results of operations could be materially and adversely
affected through an
inability to make deliveries to stores and through lost sales. In addition, these events could result in increases
in fuel (or other energy)
prices or a fuel shortage, the temporary lack of an adequate work force in a market, the temporary or long-term disruption
in the
supply of products from suppliers, delay in the delivery of goods to our distribution centers or stores, the temporary reduction
in the
availability of products in our stores and disruption to our information systems, as noted above. These events also could have
indirect indirect
consequences, such as increases in the cost of insurance, if they were to result in significant loss of property or other insurable
damage.
We rely on services and products
provided by many vendors in the United States and abroad. These include, for example, outsourcing of manufacturing services.
In the event that any vendor suffers a bankruptcy or otherwise becomes unable to continue to provide products or services, or
fails to protect our confidential, proprietary, or other information, we may suffer operational impairments and financial losses. In addition,
while we generally monitor vendor risk, including the security and stability of our critical vendors, we may fail to properly assess and
understand the risks and costs involved in the third-party relationships, and our financial condition andcondition, results of operations and
cash flows could
be materially and adversely affected.
Omni-channel retailing
is rapidly evolving, and we must keep pace with changing customer expectations and new developments by our competitors. Our customers
are increasingly using computers, tablets, mobile phones, and other devices to shop online. As part of our omni-channel strategy,
we have made and will continue to make technology investments to expand our online distribution. If we are unable to make, improve, or
develop relevant customer-facing technology in a timely manner, our ability to compete and our business and results of operations
could be materially and adversely affected. In addition, if our e-commerce businesses or our other customer-facing technology
systems do not function as designed, we may experience a loss of customer confidence, lost sales, or data security breaches, any of which
could materially and adversely affect our business andbusiness, results of operations.operations and cash flows.
We are a “controlled company”
within the meaning of the Nasdaq rules and, as a result, qualify for, and may rely on, exemptions and relief from certain corporate governance
requirements. If we rely on these exemptions, our stockholders will not have the same protections afforded to stockholders of companies
that are subject to such requirements.
Our Chief Executive Officer
and Chairman, Jack Ross, beneficially owns approximately 55% of the voting power of our common stock as of December 31, 2024. As a result,
we are a “controlled company” within the meaning of the Nasdaq corporate governance standards. Under these corporate governance
standards, a company of which more than 50% of the voting power in the election of directors is held by an individual, group or another
company is a “controlled company” and may elect not to comply with certain corporate governance requirements. For example,
controlled companies are not required to have:
While we do not intend to rely
on the exemptions relating to being a “controlled company” within the meaning of the Nasdaq rules, we may utilize these exemptions
for as long as we continue to qualify as a “controlled company.” Accordingly, our stockholders may not have the same protections
afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. Investors may find our
common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
Our success depends, in a
large large
degree, on the skills of our management team and our ability to retain, recruit and motivate key officers and employees. Our active
senior senior
executive leadership team, including Jack Ross,Ross and Jaime Fickett and Alfred Baumeler,Fickett, have significant experience, and their knowledge and relationships
relationships would be difficult to replace. Leadership changes will occur from time to time, and we cannot predict whether significant resignations
resignations will occur or whether we will be able to recruit additional qualified personnel. Competition for senior executives and skilled personnel
personnel in our industry is intense, which means the cost of hiring, paying incentives and retaining skilled personnel may continue to
increase.
We need to continue to attract
and retain key personnel and to recruit qualified individuals to succeed existing key personnel to ensure the continued growth and successful
operation of our business. In addition, we must attract and retain qualified personnel to continue to grow our business, and competition
for such personnel can be intense. Our ability to effectively compete for senior executives and other qualified personnel by offering
competitive compensation and benefit arrangements may be restricted by cash flow and other operational restraints. The loss of the services
of any senior executive or other key personnel, or the inability to recruit and retain qualified personnel in the future, could have a
material adverse effect on our business, financial condition orcondition, results of operations.operations and cash flows. In addition, to attract and retain
personnel with
appropriate skills and knowledge to support our business, we may offer a variety of benefits, which could reduce our earnings
or have
a material adverse effect on our business, financial condition orcondition, results of operations.operations or cash flows.
In connection with the preparation of our consolidated financial statements as of and for the year ended December 31, 2025, management identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls over financial reporting, which may cause us to fail to meet our reporting obligations, result in material misstatements of our consolidated financial statements and could have a material adverse effect on our business and the market price of our common stock.
As a public company, we are required to maintain internal control over financial reporting, to report any material weaknesses in such internal control, and provide management’s attestation on internal control over financial reporting. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of an entity’s financial statements will not be prevented or detected on a timely basis. If we are unable to establish or maintain appropriate internal control over financial reporting or implement these requirements in a timely manner or with adequate compliance, it could result in material misstatements in our consolidated financial statements, failure to meet our reporting obligations on a timely basis, increases in compliance costs, and subject us to adverse regulatory consequences, all of which may adversely affect investor confidence and the value of our common stock.
As discussed below in Part II, Item 9A, “Controls and Procedures,” our management identified material weaknesses in implementation of segregation of duties and establishment of clearly defined roles within our finance and accounting functions. Moreover, management concluded that its internal control over financial reporting was not effective as of December 31, 2025, due to the material weaknesses. The material weaknesses did not result in any material misstatements to our consolidated financial statements or any changes to previously filed financial statements, and management has concluded that our financial statements and other financial information included in this Annual Report, and other periodic filings, fairly present our financial condition, results of operations, and cash flows for the periods in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
We are committed to remediating the material weaknesses described above and continuing remediation efforts during 2026. We intend to initiate and implement several remediation measures including, but not limited to clearly define roles and responsibilities. As part of its remediation measures, to date, we have investigated additional procedures we can implement for segregation. While our efforts are ongoing, we plan to continue to take additional steps to remediate the material weaknesses, improve our financial reporting systems, and implement new policies, procedures, and controls; however, we cannot guarantee those measures will prevent or detect material weaknesses in the future. If we fail to remediate the material weaknesses or any future deficiencies, or fail to otherwise maintain the adequacy of our internal controls, that could result in a restatement of our financial statements for prior periods, a decline in the market price of our common stock, one or more investigations or enforcement actions by state or federal regulatory agencies, stockholder lawsuits, or other adverse actions requiring us to incur defense costs or pay fines, settlements, or judgments.
Congress and/or regulatory agencies may
impose additional laws or regulations or change current laws or regulations, and state attorneys general may increase enforcement of
existing existing
or new laws, and compliance with new or changed governmental regulations, or any state attorney proceeding, could increase our
costs significantly
and materially and adversely affect our business, financial condition andcondition, results of operations.operations and cash flows.
From time to time, Congress,
the FDA, the FTC, or other federal, state, local or foreign legislative and regulatory authorities may impose additional laws or regulations
that apply to us, repeal laws or regulations that we consider favorable to us or impose more stringent interpretations of current laws
or regulations. We are not able to predict the nature of such future laws, regulations, repeals or interpretations or to predict the effect
that additional governmental regulation, when and if it occurs, would have on our business in the future. Those developments could require
reformulation of certain products to meet new standards, recalls or discontinuance of certain products (including products that we sell)
not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products,
additional or different labeling, additional scientific substantiation, adverse event reporting or other new requirements. For example,
in recent years, the FDA has issued warning letters to several cosmetic companies alleging improper claims regarding their cosmetic
products. If the FDA determines that we have disseminated inappropriate drug claims for our products intended to be sold as cosmetics,
we could receive a warning or untitled letter, be required to modify our product claims or take other actions to satisfy the FDA. Any
developments of this nature could increase our costs significantly and could have a material adverse effect on our business, financial
condition andcondition, results of operations.operations and cash flows.
The FTC has instituted numerous
enforcement actions against dietary supplement companies for failure to have adequate substantiation for claims made in advertising or
for the use of false or misleading advertising claims. Failure by us to comply with applicable regulations could result in substantial
monetary penalties, which could have a material adverse effect on our financial condition orcondition, results of operations.operations or cash flows.
Even when unmerited, class
claims, action by the FTC or state attorneys
general enforcement actions can be expensive to defend and adversely affect our reputation
with existing and potential customers and consumers
and our corporate and brand image, which could have a material and adverse effect
on our business, financial condition orcondition, results of operations.operations
or cash flows. The number of private consumer class actions relating to false or deceptive
advertising against nutritional supplement
companies has increased in recent years. In addition, the FDA has aggressively enforced
its regulations with respect to different
types of product claims that may or may not be made for food products. These events could interrupt
the marketing and sales of our products,
severely damage our brand reputation and public image, increase our legal expenses, result in
product recalls or litigation, and impede
our ability to deliver our products in sufficient quantities or quality, which could result
in a material adverse effect on our business,
financial condition, results of operations and cash flows.
If we fail to protect the integrity and
security of customer-related and other confidential information, we could be exposed to litigation, increased costs and reputational
damage, and our business, results of operationsoperations, cash flows and financial condition could be materially and adversely affected.
The use of individually identifiable
data by us, our customers, and others is regulated at the state, federal and international levels. Privacy and information security laws
and regulations change from time to time, and there may not always be clear guidance from the respective governments and regulators regarding
the interpretation of these laws and regulations, which may create the risk of an inadvertent violation. In addition, the increasing costs
of compliance with those laws and regulations and related technology investments could materially and adversely affect our businessbusiness, results
of operations and
results ofcash operations.flows. Additionally, the success of our e-commerce operations depends upon the secure transmission of confidential
information over public networks, including the use of cashless payments, and we use computers in substantially all other aspects of our
business operations. Such uses give rise to cybersecurity risks, including security breach, espionage, system disruption, theft and inadvertent
release of information. While we have taken significant steps to protect customers’ personal information, consumer preferences and
credit card information, and other confidential information, including our employees’ private information and financial and strategic
data about the Company and our business partners, our suppliers or others may undermine our security measures. As a result, unauthorized
parties may obtain access to our data systems and misappropriate confidential data. Furthermore, because the methods used to obtain unauthorized
access change frequently and may not be immediately detected, we may be unable to anticipate these methods or implement preventative measures,
and our incident response efforts may not be entirely effective. Any preventative measures we implement may have the potential to negatively
affect our relations with our customers or decrease activity on our websites or apps by making them less user-friendly. If our data security
is compromised, it could have a material adverse effect on our reputation, results of operationsoperations, cash flows and financial condition,
materially increase
the costs we incur to protect against those events in the future and subject us to additional legal risk and a competitive
disadvantage disadvantage
and damage to our brand reputation. In addition, our customers could lose confidence in our ability to protect their personal
information, information,
which could cause them to stop using our websites or apps. We are reliant on third-party electronic payment systems
and platforms,
such as PayPal, Stripe, Amazon Pay, AfterpayAfterpay, Tik-Tok and Shopify Payments, not only to protect the security of the information
stored, but also
to appropriately track and record data. Any failures or inadequacies in these third-party systems, even if unrelated
to our business,
could result in significant liability, could materially and adversely affect our reputation and business and could cause
government agencies
to enact additional regulatory requirements or to modify their enforcement or investigation activities.
U.S. generally accepted
accounting principlesGAAP and related
pronouncements, implementation guidelines and interpretations with regard to a wide variety of matters
that are relevant to our business,
such as, but not limited to, revenue recognition, stock-based compensation, trade promotions,
and income taxes are highly complex
and involve many subjective assumptions, estimates and judgments by our management. Changes to these
rules or their interpretation or
changes in underlying assumptions, estimates or judgments by our management could significantly change
our reported results.
In addition, if the market for stocks in our industry or the stock market, in general, experience a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, results of operations, or financial condition. The trading price of our common stock might also decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. If our stock price is volatile, we may become the target of securities litigation. Securities litigation could result in substantial costs and divert our management’s attention and resources from our business. This could have a material adverse effect on our business, results of operations, cash flows and financial condition.
A significant number of our total outstanding
shares are restricted from immediate resale, but may be sold into the market in the near future. This could cause the market price of
our common stock to drop significantly, even if our business is doing well.
Subject to certain exceptions,
without the prior written consent of Roth Capital Partners, LLC, the underwriter in our initial public offering, we, and our officers
and directors and our 5% and greater stockholders, until April 20, 2025, have agreed not to: (1) offer, sell, contract to sell, pledge,
grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of common stock
or any securities convertible into, exchangeable for or that represent the right to receive shares of common stock; (2) file any
registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable
or exchangeable for common stock; or (3) enter into any swap or other arrangement that transfers, in whole or in part, any of the
economic consequences of ownership of common stock, subject to certain exceptions. Roth Capital Partners, LLC, in its sole discretion,
may release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any time
with or without notice.
The market price of our common
stock may decline significantly when the restrictions on resale by our existing stockholders lapse. A decline in the market price of our
common stock might impede our ability to raise capital through the issuance of additional shares of common stock or other equity securities.
We currently intend to retain
our future earnings, if any, for the foreseeable future, to repay indebtedness and to fund the development and growth of our business.
We do not intend to pay any dividends to holders of our common stock in the foreseeable future. Any decision to declare and pay dividends
in the future will be made at the discretion of our Board taking into accountconsidering various factors, including our business, operating results
and financial
condition, current and anticipated cash needs, plans for expansion, any legal or contractual limitations on our ability
to pay dividends
under our loan agreements or otherwise. As a result, if our Board does not declare and pay dividends, the capital appreciation
in the
price of our common stock, if any, will be your only source of gain on an investment in our common stock, and you may have to sell some
some or all of your common stock to generate cash flow from your investment.
Management's Discussion & Analysis (MD&A)
Largest changes
“The Company will take the following actions if it starts to trend unfavorably to its internal profitability and cash flow projections, in order to mitigate conditions or events that would raise substantial doubt about its ability to continue as a going concern:”see in full comparison
“On May 8, 2020, we entered into a Third Amendment Agreement (the “Third Amendment”) to the Amended and Restated Loan Agreement (the “Loan Agreement”) with Knight, pursuant to which Knight agreed to loan us an additional $2.5 million (the “Additional Loan”). That same day (the “Closing”), we paid Knight a work fee of $36,000, and $25,000 for Knight’s legal costs and expenses incurred in connection with the Third Amendment. The Third Amendment amends the original loan agreement that we entered into with Knight in January 2015 and subsequently amended (as amended, the “Original Loan Agreement”). …”see in full comparison
“On June 6, 2024, we entered into a Sixth Amendment Agreement (the “Sixth Amendment”) to the Loan Agreement with Knight. This amendment amends certain sections and inserts or restates certain definitions. In addition, we are obligated to pay Knight principal of $1,000,000 at the end of the fiscal quarters ending March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025, with the outstanding balance of the loan due on the maturity date. Additionally, we are obligated to pay Knight all accrued and unpaid interest on the principal amount monthly, on the last day of each month. …”see in full comparison
“We have utilized various short-term working capital arrangements from time to time (including merchant financing and settlement-related payment arrangements) to support liquidity and working capital needs. Substantially all of these arrangements were repaid prior to December 31, 2025. As of December 31, 2025, the primary short-term amount outstanding relates to the Cedar Advance LLC receivables purchase arrangement described below. For additional information, see the notes to our consolidated financial statements.”see in full comparison
“The Fifth Amendment amended our financial covenants to be as follows: We will maintain a minimum EBITDA of $1,000,000 for the three (3) month period ending on the last day of each Fiscal Quarter starting June 30, 2023. We shall at all times maintain FOCUSfactor net sales on a trailing twelve-month basis of at least $30,000,000.”see in full comparison
“During March 2024, the Company entered into an Amended Agreement with Knight Therapeutics for its existing secured debt, which we finalized in June 2024. The consolidated loan will bear minimum interest rate at 12% per annum compounded quarterly and will be paid on the last day of each month. The principal repayment will begin in the first quarter of 2025 with $1,000,000 due quarterly until March 31, 2026 when the loan becomes due in full. As part of this agreement the outstanding royalties of $536,730 were converted to long term debt.”see in full comparison
Full comparison: every changed paragraph (64)
The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the auditedconsolidated
condensed consolidated financial statements and the notes thereto contained elsewhere in this Annual Report. Certain information contained
in the discussion
and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results
may differ significantly
from the results, expectations and plans discussed in these forward-looking statements.
Our management’s discussion
and analysis of our financial condition and results of operations are only based on our current business and should be read in conjunction
with our unaudited interim condensed consolidated financial statements and audited consolidated financial statements and accompanying
notes thereto included elsewhere in this prospectus.Annual Report. Key factors affecting
our results of operations include revenues, cost of revenue,
operating expenses and income and taxation.
We believe that EBITDA, viewed
in addition to, and not in lieu of, our reported results in accordance with accounting principles generally accepted in the United States
(“U.S. GAAP”),GAAP, provides useful information to investors.
EBITDA is considered a non-GAAP
financial measures.measure. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not
be comparable to similarly titled measures reported by other companies.
The decrease in our Nutraceutical category was due to a shift in management focus on developing new products for the Beverages category and an overall decrease in sales. The decrease in our Beverage category was due to limited test during 2024 in Canada.
During first and second quarter of 2025, we licensed our FOCUSfactor and Flat Tummy intellectual property for $2,900,000 and we recognized revenue for the license fee at that time. During fourth quarter of 2025, due to the instability in the regions the licensee was expanding to, the entity canceled its license with the Company resulting in a reversal of the revenue of the same $2,900,000.
For the year ended December
31, 2024, our Nutraceuticals revenue consisted of $30,798,145 from our FOCUSfactor brand and $4,019,188 from our Flat Tummy brand, as
compared to $37,202,521 and $5,550,531, respectively, for the year ended December 31, 2023.
The decrease in our Nutraceutical
category was due to undertaking a rebranding and packaging upgrade for FOCUSfactor that resulted in customers selling through their existing
inventory before bringing in the new packaging. The decrease in the Consumer Goods category is due to normalization of business after
the 2019 launch of our online application.
For the year ended December 31, 2024,
2025, our cost of sales was $11,191,224.
$10,077,992. Our cost of sales for the year ended December 31, 20232024 was $10,697,323.$11,191,224. The increasedecrease in
cost of sales was primarily due to alower settlement
with a supplier in 2023 resulting in a reduction in cost of sales for 2023.revenue.
Gross profit was $23,643,019,$20,302,817,
or 68%67% of revenue for the year ended December 31, 2024,2025, as compared to gross profit of $32,080,310$23,643,019 or 75%68% of revenue for the same
period in 2023,2024, a decrease of $8,437,291$3,340,202 or 26%.14%. The decrease in gross profit is largely related to thelower decrease in net sales due to
the rebranding of FOCUSfactor.revenue.
For the year ended December 31,
2024, 2025, our selling and marketing
expenses were $12,991,431$13,137,779 as compared to $15,188,528$12,991,431 for the year ended December 31, 2023.2024. The decrease
increase is duerelated to managementthe mix of
advertising expenses.utilized.
For the year ended December 31, 2025, our general and administrative expenses were $8,829,803. For the year ended December 31, 2024, our general and administrative expenses were $4,717,006. The increase is largely due to an increase in professional fees, legal expense, board of directors’ expense, the write off of prepaid media credits carried over from 2024 and the increased overhead as we build the beverage division.
Reserve for Bad Debts
For the year ended December 31, 2025, our reserve for bad debts was $6,660,650 compared to $0 for the year ended December 31, 2024. The increase is due to the write off of a related party loan receivable of $4,403,804, a write off of uncollectible other receivables of $1,654,249, a write off of uncollectible accounts receivable of $225,018 and recognizing an allowance for doubtful accounts of $377,579.
For the year ended December 31,
2024, our general and administrative expenses were $4,717,006. For the year ended December 31, 2023, our general and administrative
expenses were $6,051,703. The decrease is largely due to management of expenses.
For both the yearyears ended
December 31, 2025 and 2024, our depreciation and amortization
expenses were $133,334 as compared to $33,333 for the year ended December 31, 2023. The increase is due to full year of amortization
on license fee during 2024.$133,334.
The increasedecrease in other income
in 20242025 iswas related to Employee Retention
Credits and an insurance claim on stolen goods.goods from 2024 that did not repeat. The decreaseincrease in
interest expense in 20242025 was primarily due to reductionan inadvance interesttaken, rateshares uponissued related to the modification of notes payable and the amortization
of original debt discount on the May 2025 loan. The gain on settlement of notes payable relates to discounts negotiated on loan payoffs
consolidation.during 2025.
For the year ended December 31, 2025, we incurred income tax expense of $117,471. For the year ended December 31, 2024 we incurred income tax expense of $102,085.
For the year ended December 31,
2024, we incurred income tax expense of $102,085. For the year ended December 31, 2023 we incurred income tax expense of $234,980.
The decrease in 2024 relates to estimated future taxes.
Net Income (Loss)
For the year ended December 31,
2024,2025, our net incomeloss was $2,124,976.$12,341,208. For the year ended December 31, 20232024 our net income was $6,338,750.$2,124,976. This decrease was due to
lower revenuerevenue, duehigher toexpenses, undertakingthe awrite rebrandingoff of other receivables and packagingthe upgradewrite foroff FOCUSfactor that resulted in customers selling through their existing
inventory before bringing inof the newloan packaging.receivable.
As of December 31, 2024,2025,
we we
had $687,920$2,622,313 cash onand handcash equivalents and restricted cash of $100,000 which is held for credit card collateral.
The Company will take the
following actions if it starts to trend unfavorably to its internal profitability and cash flow projections, in order to mitigate conditions
or events that would raise substantial doubt about its ability to continue as a going concern:
On May 30, 2025, we entered into a term credit loan agreement of $17,500,000 with ACP Agency, LLC. We received $15,000,000 in May 2025 on the initial draw and $2,500,000 in June 2025 on a delayed draw. The proceeds of the loan were used to repay existing debt, including the payoff of the Company’s indebtedness to Knight Therapeutics. We recorded $2,385,954 as original debt discount and is being amortized to interest expense over the term of the loan. We recognized $360,511 as amortization during the year ended December 31, 2025. The unamortized balance amounts to $2,025,443 at December 31, 2025. The note bears interest at Term SOFR rate, plus 8.5%, currently 12.5% and matures on May 31, 2029. We recognized total interest expense of $1,326,732 as of December 31, 2025. The outstanding loan balance at December 31, 2025 was $17,500,000 (See Note 11).
We previously had secured indebtedness with Knight Therapeutics (Barbados) Inc. and related arrangements. During 2025, this indebtedness was repaid in full in connection with the Company’s refinancing transactions, including the ACP term loan described above. For additional information regarding our prior Knight indebtedness and the related repayment, see the notes to our consolidated financial statements.
On June 26, 2015, we,
through our wholly owned subsidiary, Neuragen Corp. (“Neuragen”), issued a 0% promissory note in a principal amount of $950,000
in connection with an Asset Purchase Agreement. The note required that $250,000 be paid on or before June 30, 2016, and $700,000
to be paid in quarterly installments (beginning with the quarter ending September 30, 2015) equal to the greater of $12,500 or 5%
of U.S. net sales, and 2% of U.S. net sales of Neuragen for 60 months thereafter. The payment of such amounts was secured
by a security interest in certain assets, undertakings and property (“Collateral”) pursuant to the Security Agreement, which
will be released upon receipt of total payments of $1.2 million. During March 2024, this Security Agreement was consolidated
with the other outstanding loans to Knight Therapeutics (Barbados) Inc. (“Knight”).
On August 9, 2017, we
entered into a Second Amendment to Loan Agreement (“Second Amendment”) with Knight, pursuant to which Knight agreed to loan
us an additional $10 million, and an ongoing credit facility of up to $20 million, and which amount was borrowed at closing
(the “Financing”) for working capital purposes. At closing, we paid Knight an origination fee of $200,000 and a work fee
of $100,000 and also paid $100,000 of Knight’s expenses associated with the Loan.
On May 8, 2020, we entered
into a Third Amendment Agreement (the “Third Amendment”) to the Amended and Restated Loan Agreement (the “Loan Agreement”)
with Knight, pursuant to which Knight agreed to loan us an additional $2.5 million (the “Additional Loan”). That same day
(the “Closing”), we paid Knight a work fee of $36,000, and $25,000 for Knight’s legal costs and expenses incurred in
connection with the Third Amendment. The Third Amendment amends the original loan agreement that we entered into with Knight in January 2015
and subsequently amended (as amended, the “Original Loan Agreement”). The Additional Loan matured on May 8, 2021 (the
“TA Maturity Date”) and bore interest at 12.5% per annum compounding quarterly. On the TA Maturity Date, we were obligated
to pay Knight a success fee (the “Success Fee”) of $83,250. The Success Fee was payable in cash or stock as set forth in the
Loan Agreement. The Third Amendment includes customary representations, warranties, and affirmative and restrictive covenants, including
covenants to attain and maintain certain financial metrics, including an undertaking to maintain at all times a cash balance of $600,000
and EBITDA of $3,000,000 for the twelve months ended June 30, 2020 and $4,000,000 for the twelve-month period ending on the
last day of each fiscal quarter thereafter.
Terms of the $10,000,000 August 9,
2017 loan (“Third Tranche”) were modified in the Third Amendment. The Third Tranche bore interest from May 8, 2020 at
a rate equal to 12.5% per annum compounded quarterly. We were obligated to pay a success fee in the amount of $1,000,000 with respect
to the Third Tranche, which was fully earned on May 8, 2020 and payable no later than August 31, 2022. The Third Tranche success
fee bore interest at 12.5% per annum compounding quarterly. The loan was extended to a maturity date of December 31, 2021. Because
these amendments were considered not substantive changes, we accounted for the modifications as modification of debt.
On July 7, 2022, we
entered into a Fourth Amendment Agreement (the “Fourth Amendment”) to the Loan Agreement with Knight, pursuant to which
Knight agreed to loan us an additional $2.0 million (the “Second Additional Loan”). The Fourth Amendment amended
the Original Loan Agreement. The Second Additional Loan matured on the earlier of October 31, 2022 and the date that is
ninety days after the date, if any, on which Knight delivers a Second Additional Loan Repayment Notice to us. We were obligated
to pay Knight a success fee of $40,000 and an amendment fee of $30,000 which was fully earned and payable as of the Fourth Amendment
Date. The loan bore interest at the greater of 14% or the prime rate plus 8% per annum, compounded quarterly. This $2.0 million
Second Additional Loan (only) had a personal guarantee by Jack Ross, our chief executive officer and chairman of the board.
On September 30, 2023,
we entered into a Fifth Amendment Agreement (the “Fifth Amendment”) to the Loan Agreement with Knight, pursuant to which Knight
agreed to extend the maturity date of the Loan to March 31, 2024. The loan bore interest at 15.5% per annum compounding quarterly.
We were obligated to pay Knight a closing fee of $1,000,000 and $150,000 as reimbursement for Knight’s legal fees incurred in connection
with the Fifth Amendment. These have been accrued for during the year ended December 31, 2022 since this was earned upon renegotiation
of the loan during 2022. We have also paid Knight an extension fee of $136,000 per month from October 2023 through February 2024.
The Fifth Amendment amended
our financial covenants to be as follows: We will maintain a minimum EBITDA of $1,000,000 for the three (3) month period ending on
the last day of each Fiscal Quarter starting June 30, 2023. We shall at all times maintain FOCUSfactor net sales on a trailing
twelve-month basis of at least $30,000,000.
On October 1, 2023 (effective
date), we entered into a second amendment to the Distribution Agreement with Knight with an initial term ending on February 25, 2026
and an automatic renewal of one year for a payment of $450,000 by us within 180 days from the effective date. We have recorded this
payable in terms of a Note Payable to Knight Therapeutics in relation to a license fee of an intangible asset. The balance outstanding
at December 31, 2023 was $450,000.
During March 2024, the
Company entered into an Amended Agreement with Knight Therapeutics for its existing secured debt, which we finalized in June 2024. The
consolidated loan will bear minimum interest rate at 12% per annum compounded quarterly and will be paid on the last day of each
month. The principal repayment will begin in the first quarter of 2025 with $1,000,000 due quarterly until March 31, 2026 when the
loan becomes due in full. As part of this agreement the outstanding royalties of $536,730 were converted to long term debt.
On June 6, 2024, we entered
into a Sixth Amendment Agreement (the “Sixth Amendment”) to the Loan Agreement with Knight. This amendment amends certain
sections and inserts or restates certain definitions. In addition, we are obligated to pay Knight principal of $1,000,000 at the end of
the fiscal quarters ending March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025, with the outstanding
balance of the loan due on the maturity date. Additionally, we are obligated to pay Knight all accrued and unpaid interest on the principal
amount monthly, on the last day of each month. The final payment will be on the maturity date. One of the covenants was updated so
that we must maintain a minimum EBITDA of $1,250,000 for the three-month period ending on the last day of each fiscal quarter, starting
March 31, 2024. In addition, we must provide Knight our quarterly and annual operating budget for approval prior to implementation.
On February 10, 2022,
we entered into a promissory note for $2,000,000 with an individual which was to be repaid with subsequent financing. On March 31,
2024, we entered into a Modification Agreement in relation to this loan. Effective March 31, 2024, the interest rate is 12%, compounded
quarterly. Cash payments of interest shall be made monthly, on the final day of each month commencing in April 2024. We are
required to make principal payments of $1,000,000 each quarter starting from March 31, 2025 until December 31, 2025. The remaining
principal and unpaid interest is fully due on March 31, 2026. In addition, a loan renegotiation fee of $500,000 shall be earned and
and payable on March 31, 2026 or at such time the loan is paid in full. Upon closing of a sale transaction, as defined in the agreement,
a bonus success fee of $1,800,000 will be earned and payable. An event of default, as defined in the agreement, will trigger a default
interest rate increase by 5% to 17%. An incentive fee of a maximum of $563,092 will be paid, prorated if the loan is paid off early.
If the loan is not repaid by March 31, 2026, Jack Ross, majority shareholder, shall grant warrants covering 10% of his stock struck
at $0.12 per share. There
is a cross-default clause in the agreement which states that if Knight triggers an event of default on its
own loan facility, this loan
will also be under default. This Agreement consolidates this $2,000,000 loan and the $6,000,000 March 8,
2022 loan as detailed below.
On March 8, 2022, we
entered into Securities Purchase Agreements with debenture holders for the Senior Subordinated Debentures in the amount of $6,000,000
$6,000,000 with an original maturity date of September 8, 2022 and warrants equal to the principal amount with a term of 3 years. The Senior
Subordinated Debentures were modified on June 14, 2023 inand conjunctionconsolidated with the promissory note.note dated February 10, 2022. The modification
included the
exercise of $1.5a million on$1,500,000 cash payment in lieu of the exercise of warrants. Pursuant to ASC 480 warrants were liability
liability classified and we accrued the warrant liability of $1.5 million$1,500,000 on March 8, 2022, the date of issuance. Upon
On September 8, 2022,
the date of exercise of the warrants, we offset this warrant liability and added the $1.5$1,500,000 million
balance to the Senior Subordinated Debentures,
for a combined outstanding balance of $7.5 million.$7,500,000. The terms of the warrants
were, at the sole option of the holder, to convert the warrant
at a 25% discount in the event we consummated an IPO, a cash option
whereby the holder could convert the warrants at a cash value of $1.5 million $1,500,000
or convert the warrants into the private entity
valued by an independent third-party appraiser. On March 31, 2024, we entered into
a Modification Agreement in relation to this
loan, which consolidates it with the $2,000,000 February 10, 2022 loan above.
We have utilized various short-term working capital arrangements from time to time (including merchant financing and settlement-related payment arrangements) to support liquidity and working capital needs. Substantially all of these arrangements were repaid prior to December 31, 2025. As of December 31, 2025, the primary short-term amount outstanding relates to the Cedar Advance LLC receivables purchase arrangement described below. For additional information, see the notes to our consolidated financial statements.
On May 10, 2022, we entered
into a loan agreement of $355,950 with Shopify Capital Inc. for an advancement of working capital from our online processing account.
We received $315,000 from Shopify Capital Inc. and $40,950 was an original issue discount. The loan bears a repayment rate of 17% of daily
sales. The payment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to the Security
Agreement, which will be released upon receipt of total payments of $355,950. We recognized amortization original issue discount of $13,746,
which is included in interest expense in the statement of income during the year ended December 31, 2023. The outstanding loan
balance at December 31, 2023 was $0.
On April 13, 2023, we
entered into a loan agreement of $226,000 with Shopify Capital Inc. for an advancement of working capital from our online processing account.
We received $200,000 from Shopify Capital Inc. and $26,000 was an original issue discount. The loan bears a repayment rate of 17% of daily
sales. The payment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to the Security
Agreement, which will be released upon receipt of total payments of $226,000. We recognized amortization original issue discount of $26,000,
which is included in interest expense in the statement of income during the year ended December 31, 2023. The outstanding loan balance
at December 31, 2023 was $0.
On July 12, 2023, we entered
into a loan agreement of $180,800 with Shopify Capital Inc. for an advancement of working capital from our online processing account.
We received $160,000 from Shopify Capital Inc. and $20,800 was an original issue discount. The loan bears a repayment rate of 17% of daily
sales. The payment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to the Security
Agreement, which will be released upon receipt of total payments of $180,800. We recognized amortization original issue discount of $12,288
and $8,512, respectively, which are included in interest expense in the statement of income during the years ended December 31, 2024
and 2023. The outstanding loan balance at December 31, 2024 and 2023 was $0 and $94,525, respectively.
On December 28, 2023,
we entered into a confidential settlement agreement and mutual general release with a former supplier. The loan bears interest at 5% per
annum and is payable in full with the last payment. This settlement resulted in a gain to us of $2,235,986 and is reflected as a reduction
of cost of sales (See Note 13). During 2024 and 2023, we made payments of $2,000,000 and $1,000,000, respectively, toward this loan.
The outstanding loan balance at December 31, 2024 and 2023 was $2,802,445 and $4,802,445, respectively, including interest of $352,445.
On January 21, 2024, we
entered into a loan agreement of $141,250 with Shopify Capital Inc. for an advancement of working capital from our online processing account.
We received $125,000 from Shopify Capital Inc. and $16,250 was an original issue discount. The loan bears a repayment rate of 17% of daily
sales. The payment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to the Security
Agreement, which will be released upon receipt of total payments of $141,250. We recognized amortization original issue discount of $16,250,
which is included in interest expense in the statement of income during the year ended December 31, 2024. The outstanding loan balance
at December 31, 2024 was $0.
During 2024, we received $3,175,000 USD and $514,500 CAD in exchange
for a short term note payable issued to an entity owned and controlled by our Chief Executive Officer. This was repaid during 2024 along
with interest of $525,000 USD.
On March 27, 2024 we entered
into a confidential settlement agreement and mutual general release with a supplier. During 2024, we made payments of $700,000 toward
this loan. The outstanding loan balance at December 31, 2024 was $2,320,824.
On May 1, 2024, we entered into a loan agreement with Shopify Capital
Inc. for an advancement of working capital from our online processing account. We received $370,000 from Shopify Capital Inc. and $48,100
was an original issue discount. The loan bears a repayment rate of 25% of daily sales. The payment of such amounts is secured by a security
interest in certain assets, undertakings and property pursuant to the Security Agreement, which will be released upon receipt of total
payments of $418,100. The Company recognized amortization original issue discount of $13,067 which is included in interest expense in
the statement of income during the year ended December 31, 2024. The outstanding loan balance at December 31, 2024 was $269,488 net of
unamortized original issue discount of $35,033.
On May 22, 2024, we
entered into a loan agreement with Shopify Capital Inc. for an advancement of working capital from our online processing account. We
received $105,000 from Shopify Capital Inc. and $13,650 was an original issue discount. The loan bears a repayment rate of 25% of
daily sales. The payment of such amounts is secured by a security interest in certain assets, undertakings and property pursuant to
the Security Agreement, which will be released upon receipt of total payments of $118,650. We recognized amortization original
issue discount of $11,515, which is included in interest expense in the statement of income during the year ended December 31, 2024.
The outstanding loan balance at December 31, 2024 was $16,425, net of unamortized original issue discount of $2,135.
On
December 5,November 2024,12, 2025, we
entered into a cash advance agreement of $800,000$3,024,000 with Cedar Advance LLC for an advancement of working capital.capital via the sale of receivables.
We received $760,000$2,000,000 and recorded $40,000$1,024,000 as interestoriginal expense.issue discount. The loan bears a repayment rate of $41,100$84,000 per week. In conjunction
with the advance, we issued 52,000 shares of common stock to the consultant who facilitated the facility and thus recognized
$103,220 as financing cost. We recognized total
interest expense of $136,000$349,435 as of December 31, 2024.2025. The outstanding loan balance
at December 31, 20242025 was $0.$1,658,215.
On January 29, 2025, we entered into a cash advance agreement of $1,575,000
with Cedar Advance LLC for an advancement of working capital. We received $1,496,250 and recorded $78,750 as interest expense. The loan
bears a repayment rate of $81,000 per week. The outstanding loan balance at March 28, 2025 was $1,008,000.
As of the date of filing
of this filing,
Annual Report, we are in compliance with allthe of thematerial terms, conditions and covenants associatedapplicable withto theour loanoutstanding agreementsdebt described above.arrangements.
Approximately $13.3 million of our outstanding indebtedness comes due
in the year ending December 31, 2025, and approximately $15.8 million comes due in the year ending December 31, 2026. We believe that
while cash provided by sales of our products will be sufficient to meet these obligations as they come due, we are currently working on
refinancing our debt obligations. As of March 25, 2025, we have approximately $0.3 million of cash. Furthermore, although BoomBod Ltd.
is obligated to repay to us the outstanding balance of $4,375,059 by December 31, 2025, we do not expect to rely on repayment of the outstanding
balance to fund our operations or meet our near-term debt obligations.
For the year ended December 31,
2024,2025, we had net cash used in operating activities of $4,803,390$2,585,022 as compared to $421,729$4,803,390 of net cash providedused byin operating activities for
for the year ended December 31, 2023.2024. The decrease was primarily due to increasesdecreases in accounts receivablereceivable, other receivables and prepaidrelated
party expensesloan and
a decrease of accounts payable and accrued liabilities.receivable.
For 2025, net cash used in operating activities of $2,585,022 consisted of our net loss of $12,341,208 adjusted by:
For 2023, net cash provided
by operating activities of $421,729 consisted of our net income of $6,338,750 adjusted by:
For the year ended December 31, 2024,
2025, net cash provided by financing
activities was $4,804,086,$4,654,664, as compared to $2,090,782$4,804,086 usedprovided inby financing activities for the year
ended December 31, 2023.2024. The increase
decrease was attributable to the issuance of common stock and proceeds from notes payable offset by
repayment on notes payable.
Financing activities during 2025:
Financing activities during
2023:
We recognize revenue upon
shipment shipment
from our fulfillment centers. Certain of our distributors may also perform a separate function as a co-packer on our behalf.
In such cases,
ownership of and title to our products that are co-packed on our behalf by those co-packers who are also distributors,
passes to such
distributors when we are notified by them that they have taken transfer or possession of the relevant portion of our finished
goods. Freight
billed to customers is presented as revenues, and the related freight costs are presented asin costselling ofand goodsmarketing sold. expense.
Cancelled orders are
refunded if not already dispatched, refunds are only paid if stock is damaged in transit, discounts are only offered
with specific promotions
and orders will be refilled if lost in transit. We recognize revenue for our digital products in the month the
download by the customer
occurs.
We account for our IP license revenue, which provides our customers with rights to use our IP, in accordance with ASC 606. A license may be perpetual or time limited in its application. In accordance with ASC 606, we continue to recognize revenue from IP license at the time of delivery when the customer accepts control of the IP, as the IP is functional without professional services, updates and technical support. We have concluded that its IP license is distinct as the customer can benefit from the functional IP on its own. Therefore, we have determined the right to use its IP was satisfied at a point in time (on the date the rights to the IP were granted).
Synergy CHC Mexico, our wholly-owned Mexican subsidiary, is subject to income taxes in the jurisdictions in which it operates. Significant judgment is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. We recognize liabilities for anticipated tax audit issues based on our current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.
What changed in the latest 10-Q
Risk Factors
As a smaller reporting company under Rule 12b-2 of the Exchange Act, we are not required to include risk factors in this Quarterly Report. However, as of the date of this Quarterly Report, there have been no material changes with respect to those risk factors previously disclosed in the “Risk Factors” section of the Annual Report. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.
Full comparison: every changed paragraph (1)
As a smaller reporting company
under Rule 12b-2 of the Exchange Act, we are not required to include risk factors in this Quarterly Report. However, as of the date of
this Quarterly Report, there have been no material changes with respect to those risk factors previously disclosed in the “Risk
Factors” section of the Prospectus.Annual Report. Any of these factors could result in a significant or material adverse effect on our results
of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also
impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time
to time in our future filings with the SEC.
Management's Discussion & Analysis (MD&A)
Removed heading “Results of Operations for the Nine Months Ended September 30, 2025 and September 30, 2024”
Removed heading “Cost of Revenue”
Removed heading “Operating Expenses”
Removed heading “Other Income and Expenses”
Largest changes
“Results of Operations for the Nine Months Ended September 30, 2025 and September 30, 2024”see in full comparison
“Ordinarily, conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern relate to the entity’s ability to meet its obligations as they become due.”see in full comparison
This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expectedsee in full comparisonexpectedand projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation,limitation,statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regardingregardingour financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements.statements.Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations thereof and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performanceperformanceor results to differ materially from the events, performance and results discussed in the forward-looking statements. For informationinformationidentifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements,statements,please refer to the Risk Factors section of ourfinalAnnualprospectusReportforonourForminitial public offering10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) onOctober 23,April20241, 2026 (the “ProspectusAnnual Report”) and the “Risk Factors” section of thisreport.Quarterly Report. Our securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, we disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Full comparison: every changed paragraph (51)
This Quarterly Report includes
“forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act that
are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected
expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation,
limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding
regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements.
statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,”
“intends,” “may,” “might,” “plan,” “possible,” “potential,”
“predict,”
“project,” “should,” “would” and variations thereof and similar words and expressions
are intended
to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance,
but reflect
management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance
performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information
information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements,
statements, please refer to the Risk Factors section of our finalAnnual prospectusReport foron ourForm initial public offering10-K filed with the U.S. Securities and Exchange Commission (the
“SEC”) on October
23,April 20241, 2026 (the “ProspectusAnnual Report”) and the “Risk Factors” section of this report.Quarterly Report.
Our securities filings can be accessed
on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by
applicable securities law, we disclaim
any intention or obligation to update or revise any forward-looking statements whether as a result
of new information, future events or
otherwise.
We are a provider of consumer
health care, beauty, and lifestyle products. Our current brand portfolio consists of two core brands: FOCUSfactor, a clinically-tested
brain health supplement (this study was performed independently and is not related to any FDA-approved Investigational New Drug application)
that has been shown to improve memory, concentration and focusfocus, and Flat Tummy, a lifestyle brand that provides a suite of nutritional
products to help women achieve their weight management goals.
EBITDA is considered a non-GAAP
financial measures.measure. EBITDA represents earnings before interest, taxes, depreciation and amortization. Our definition of EBITDA might not
be comparable to similarly titled measures reported by other companies.
Results of Operations for the Three Months
Ended SeptemberMarch 30,31, 20252026 and SeptemberMarch 30,31, 20242025
During both the three months
ended SeptemberMarch 30,31, 20252026 and 2024,2025, we focused on developing our currently owned brands into new markets and by product extensions. Our objective
objective is to grow our two targeted verticals (Nutraceuticals and Ready To Drinks (RTDs)) to provide a balanced and synergistic portfolio that
that drives consumer demand via multiple channels. Our Nutraceuticals vertical consists of FOCUSfactor, including RTDs, and Flat Tummy
consumables.
For the three months ended
SeptemberMarch 30,31, 2025,2026, we had revenue of $8,010,112$5,492,705 from sales of our productsproducts, as compared to revenue of $7,126,333$8,170,534 for the three months
ended SeptemberMarch 30,31, 2024.2025. The revenue is comprised of the following categories:
We had a decrease in Nutraceuticals revenue in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 due to a decrease in online sales. We had an increase in Beverages revenue in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 due to new retail distribution. We had a decrease in License Revenue in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 as that was a one-time item that did not repeat.
We had an increase in Nutraceuticals
revenue in the three months ended September 30, 2025 as compared to the three months ended September 30, 2024 due to a packaging
upgrade that occurred in 2024 which delayed shipments that did not repeat in 2025.
For the three months ended
SeptemberMarch 30,31, 2025,2026, our cost of revenue was $2,329,296.$1,521,910. Our cost of revenue for the three months ended SeptemberMarch 30,31, 2024,2025, was $2,335,901.$2,006,513.
The decrease in cost of sales was primarily due to productthe mixdecrease sold.in revenue.
Gross profit was $5,680,816,$3,970,795,
or 71%72% of revenue, for the three months ended SeptemberMarch 30,31, 2025,2026, as compared to gross profit of $4,790,432,$6,164,021, or 67%75% of revenue, for the
the same period in 2024,2025, ana increasedecrease of $890,384,$2,193,226, or 19%.36%. The increasedecrease in gross profit is directly related to the productlicense mixrevenue sold.in 2025.
For the three months ended
SeptemberMarch 30,31, 2025,2026, our selling and marketing expenses were $2,729,767$2,455,732 as compared to $2,509,440$2,876,271 for the three months ended SeptemberMarch 31,
30, 2024,2025, which is anprimarily immaterialdue increase.to lower revenue.
For the three months ended March 31, 2026, our general and administrative expenses were $2,048,850. For the three months ended March 31, 2025, our general and administrative expenses were $1,306,714. The increase is largely due to increased salaries and benefits, stock-based compensation, board compensation and professional fees.
For the three months ended
September 30, 2025, our general and administrative expenses were $1,637,706. For the three months ended September 30, 2024, our general
and administrative expenses were $1,196,784. The increase is primarily due to public market expenses.
For both the three months
ended ended
SeptemberMarch 30,31, 2026 and 2025, our depreciation and amortization expenses were $33,333 as compared to $33,333 for the three months ended September
30, 2024.$33,333.
For the three months ended
SeptemberMarch 30,31, 20252026 and 20242025 we had other income and expense items as follows:
For the three months ended
SeptemberMarch 30,31, 2025,2026, we had net interest expense of $1,164,402$2,012,121 as compared to $705,088$1,095,369 for the three months ended SeptemberMarch 30,31, 2024.2025. The
The increase is primarily due to thean advance taken and the amortization of original debt discount on the newMay 2025 loan.
For the three months ended
SeptemberMarch 30,31, 2025,2026, our net incomeloss was $125,327$2,568,899 as compared to a net income of $783,593$876,264 for the three months ended SeptemberMarch 30,
202431, 2025 due
to otherlower income in 2024 and higher expenses in 2025.revenue.
Results of Operations for the Nine Months Ended
September 30, 2025 and September 30, 2024
During both the nine months
ended September 30, 2025 and 2024, we focused on developing our currently owned brands into new markets and by product extensions. Our
objective is to grow our two targeted verticals (Nutraceuticals and RTDs) to provide a balanced and synergistic portfolio that drives
consumer demand via multiple channels. Our Nutraceuticals vertical consists of FOCUSfactor, including RTDs, and Flat Tummy consumables.
Revenue
For the nine months ended
September 30, 2025, we had revenue of $21,415,642 from sales of our products and $2,900,000 from a license agreement, as compared to revenue
of $24,563,039 for the nine months ended September 30, 2024. The revenue is comprised of the following categories:
We had a decrease in Nutraceuticals
revenue in the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024 due to a new product
sell-in to one customer in 2024 that did not repeat in 2025. We also had revenue from a license agreement to expand into selected foreign
territories.
Cost of Revenue
For the nine months ended
September 30, 2025, our cost of revenue was $6,232,201. Our cost of revenue for the nine months ended September 30, 2024, was $7,421,930.
The decrease in cost of sales was primarily due to the decrease in product revenue.
Gross Profit
Gross profit was $18,083,441,
or 74% of revenue, for the nine months ended September 30, 2025, as compared to gross profit of $17,141,106, or 70% of revenue, for
the same period in 2024, an increase of $942,335, or 5%. The increase in gross profit is related to the license revenue.
Operating Expenses
Selling and Marketing Expenses
For the nine months ended
September 30, 2025, our selling and marketing expenses were $8,668,249 as compared to $9,149,303 for the nine months ended September
30, 2024, which is primarily due to lower revenue and an improved management of promotions in 2025.
General and Administrative Expenses
For the nine months ended
September 30, 2025, our general and administrative expenses were $4,463,745. For the nine months ended September 30, 2024, our general
and administrative expenses were $3,449,007. The increase is primarily public market expenses.
Depreciation and Amortization Expenses
For the nine months ended
September 30, 2025, our depreciation and amortization expenses were $100,000 as compared to $100,000 for the nine months ended September
30, 2024.
Other Income and Expenses
For the nine months ended
September 30, 2025 and 2024 we had other income and expense items as follows:
For the nine months ended September
30, 2025, we had interest expense of $4,367,487 as compared to $2,560,596 for the nine months ended September 30, 2024. The increase
is primarily due to an advance taken in 2025, shares issued related to the modification of notes payable and new May 2025 loan.
Net Income
For the nine months ended
September 30, 2025, our net income was $2,474,827 as compared to a net income of $2,019,309 for the nine months ended September 30,
2024 due to a gain on loan settlements.
As of SeptemberMarch 30,31, 2025,2026, we had
had $1,006,489$292,115 cash on hand and restricted cash of $100,000 which is held for credit card collateral.
In connection with preparing unaudited condensed consolidated financial statements for the three months ended March 31, 2026, management evaluated whether there were conditions and events, considered in the aggregate, that raised substantial doubt about the Company’s ability to continue as a going concern within one year from the date that the unaudited condensed consolidated financial statements are issued.
The Company considered the following:
Ordinarily, conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern relate to the entity’s ability to meet its obligations as they become due.
We evaluated our ability to meet our obligations as they become due within one year from the date that the unaudited condensed consolidated financial statements are issued by considering the following:
For the ninethree months
ended ended
SeptemberMarch 30,31, 2025,2026, net cash used in operating activities was $3,209,149$2,044,678 compared to net cash used in operating activities of $1,377,479$822,781
for the ninethree months ended SeptemberMarch 30,31, 2024.2025. This increase in net cash used by operating activities for the ninethree months ended
SeptemberMarch 30,31, 20252026 iswas detailedprimarily attributable to a decrease in thenet table below.income.
For the ninethree months ended
SeptemberMarch 30,31, 2025,2026, net cash used in operating activities of $3,209,149$2,044,678 consisted of our net incomeloss of $2,474,827$2,568,899 adjusted by:
For the ninethree months ended
SeptemberMarch 30,31, 2024,2025, net cash used in operating activities of $1,377,479$822,781 consisted of our net income of $2,019,309$876,264 adjusted by:
For the ninethree months ended
March September
30,31, 20252026 and 2024,2025, we used net cash of $0 in investing activities.
For the ninethree months ended
SeptemberMarch 30,31, 2025,2026, net cash providedused byin financing activities was $3,515,856$307,600 compared to net cash provided by financing activities of
$895,972 $314,678 for
the ninethree months ended SeptemberMarch 30,31, 2024.2025. The increasedecrease was attributable to newdecreased loans.proceeds of notes.
Financing activities during
the ninethree months ended SeptemberMarch 30,31, 20252026 and 20242025:
During the ninethree months
ended SeptemberMarch 30,31, 2025,2026, and during the year ended December 31, 2024,2025, we had no off-balance sheet arrangements.
The effect of inflation on
our operating results was not significant in the ninethree months ended SeptemberMarch 30,31, 20252026 or 2024.2025.
SNYRQ insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-21 | Kaushal Nitin |
Grant/award | 306,433 | — | — |
| 2026-04-21 | Thompson Teresa Brigid |
Grant/award | 25,824 | — | — |
Well-known investors holding SNYRQ (13F)
| Investor | Quarter | Shares | Reported value | % of their 13F | Change vs prior quarter |
|---|---|---|---|---|---|
| Citadel Advisors (Ken Griffin) | 2026-06-30 | 10,902 | $2.2K | 0.0% | New position |